<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>388</serviceExecutionTime><Drug id="6148"><DrugName>propentofylline</DrugName><DrugNamesKey><Name id="42769329">Hextol</Name><Name id="42769330">Kronos</Name><Name id="42769328">Viviq</Name><Name id="42758114">propentofylline</Name></DrugNamesKey><DrugSynonyms><Name><Value>propentofylline</Value><Types><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>Viviq</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Hextol</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Kronos</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>HWA-285</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Hoe-285</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Albert-285</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Kronos IV</Value></Name><Name><Value>55242-55-2</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="25218">Aventis Pharma AG</CompanyOriginator><CompaniesSecondary><Company id="1047743">Endogenous Stem Cells Activators Inc</Company><Company id="16807">Hoechst AG</Company><Company id="25218">Aventis Pharma AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="6148" type="Drug"><TargetEntity id="90664" type="siDrug">Propentofylline</TargetEntity></SourceEntity><SourceEntity id="1047743" type="Company"><TargetEntity id="5035525732" type="organizationId">Endogenous Stem Cells Activators Inc</TargetEntity></SourceEntity><SourceEntity id="16807" type="Company"><TargetEntity id="5035555553" type="organizationId">Hoechst AG</TargetEntity></SourceEntity><SourceEntity id="25218" type="Company"><TargetEntity id="4296758779" type="organizationId">Aventis Pharma AG</TargetEntity></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"></TargetEntity><TargetEntity id="331.0" type="ICD9"></TargetEntity><TargetEntity id="10012271" type="MEDDRA"></TargetEntity><TargetEntity id="D000544" type="MeSH"></TargetEntity><TargetEntity id="-1268969445" type="omicsDisease"></TargetEntity><TargetEntity id="101" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="540" type="ciIndication"><TargetEntity id="10003210" type="MEDDRA"></TargetEntity><TargetEntity id="D001161" type="MeSH"></TargetEntity><TargetEntity id="-1473236367" type="omicsDisease"></TargetEntity><TargetEntity id="207" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="62" type="ciIndication"><TargetEntity id="I63" type="ICD10"></TargetEntity><TargetEntity id="10008118" type="MEDDRA"></TargetEntity><TargetEntity id="D002544" type="MeSH"></TargetEntity><TargetEntity id="-1893001162" type="omicsDisease"></TargetEntity><TargetEntity id="90" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="303" type="Action"><TargetEntity id="803" type="Mechanism">cAMP Phosphodiesterase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="53558" type="Action"><TargetEntity id="4891" type="Mechanism">Drugs Targeting Cancer Stem Cells</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="W">Withdrawn</PhaseHighest><IndicationsSecondary><Indication id="14">Alzheimers disease</Indication><Indication id="540">Arteriosclerosis</Indication><Indication id="62">Cerebral infarction</Indication></IndicationsSecondary><ActionsPrimary><Action id="303">PDE inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="53558">Stem cell modulator</Action><Action id="2667">Antiarteriosclerotic</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="651">Intramuscular formulation</Technology></Technologies><LastModificationDate>2018-12-03T08:37:24.000Z</LastModificationDate><ChangeDateLast>2018-04-20T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;Presumed licensee &lt;ulink linkID="1047743" linkType="Company"&gt;Endogenous Stem Cells Activators&lt;/ulink&gt; (ESAI), was investigating the stem cell-modulating propentofylline (as Kronos IV), a vascular and neuroprotective phosphodiesterase inhibitor, for the potential off-label im treatment of Alzheimer's disease (AD) [&lt;ulink linkID="1013956" linkType="Reference"&gt;1013956&lt;/ulink&gt;]. In May 2009, ESAI was investigating the drug's use as an off-label drug for AD. At that time, the company believed that the drug would be allowed for off-label use by the FDA and the company expected that the drug would be available for use by February or March 2010 [&lt;ulink linkID="1013956" linkType="Reference"&gt;1013956&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Hoechst (now &lt;ulink linkID="25218" linkType="Company"&gt;Aventis Pharma&lt;/ulink&gt;) developed and launched the drug (as Hextrol) in Japan for cerebral infarction and arteriosclerosis [&lt;ulink linkID="167545" linkType="reference"&gt;167545&lt;/ulink&gt;]. However, in may 1998, the drug was withdrawn following the CPAC's committee on drugs re-evaluated the drug's clinical trial results and concluded that medical usefulness could not be confirmed [&lt;ulink linkID="288072" linkType="reference"&gt;288072&lt;/ulink&gt;]. Aventis was also developing the drug for AD. In October 1996, the company submitted an MAA to the EMEA for AD [&lt;ulink linkID="221118" linkType="Reference"&gt;221118&lt;/ulink&gt;]; however, in March 2000, development was discontinued after results of the 72-week propentophylline long-term use study (PLUS) showed no treatment differences between the propentophyline-treated group and the placebo-treated group [&lt;ulink linkID="358253" linkType="reference"&gt;358253&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In October 1998, Hoechst failed to get the backing of the European Commissions CPMP for the treatment of AD [&lt;ulink linkID="305859" linkType="reference"&gt;305859&lt;/ulink&gt;] after filing in September 1996 [&lt;ulink linkID="221118" linkType="reference"&gt;221118&lt;/ulink&gt;]. The company appealed this decision [&lt;ulink linkID="313155" linkType="reference"&gt;313155&lt;/ulink&gt;]; however, in March 1999, the CPMP again rejected the filing for AD and called for a further phase III trial to confirm efficacy. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In May 2009, a clinical trial was planned by ESAI to evaluated the drug's safety, pharmacology and bioavailability. In each group of 10 patients, the drug would be administered by im injection three times a week for 6 months [&lt;ulink linkID="1013956" linkType="Reference"&gt;1013956&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 1999, phase III studies were completed in the US for AD and vascular dementia. A total of 1387 patients with AD and 793 patients with vascular dementia had been enrolled in six phase III trials [&lt;ulink linkID="337131" linkType="reference"&gt;337131&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 1999, Hoechst announced that an additional pivotal phase III trial would be undertaken [&lt;ulink linkID="327690" linkType="reference"&gt;327690&lt;/ulink&gt;], [&lt;ulink linkID="333420" linkType="reference"&gt;333420&lt;/ulink&gt;]. Hoechst believed that the disparity between results of a US and an EU trial could be explained by interactions between propentofylline and food. This was to be investigated by Hoechst conducting a series of phase I trials in order to determine the potential interactions with ingestion of food. At this time, launch of the compound had been expected to take place in 2003 [&lt;ulink linkID="333420" linkType="reference"&gt;333420&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 1999, the European/Canadian Propentofylline Study Group examined propentofylline in a phase III study on 486 AD patients. Propentofylline, particularly when used early on, appeared to slow the progress of the disease [&lt;ulink linkID="325254" linkType="reference"&gt;325254&lt;/ulink&gt;], [&lt;ulink linkID="344493" linkType="reference"&gt;344493&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1998, two European phase III trials evaluated propentofylline in patients with mild-to-moderate dementia according to DSM-III-R criteria. These were double-blind, placebo-controlled, randomized, parallel-group trials. The first study followed 260 patients (129 received propentofylline 300 mg tid and 131 on placebo) for 12 months. The propentofylline-treated group displayed significant improvements on various scores (GBS total, CGI item II, MMSE, SKT). The second trial studied 550 patients, of whom 265 received propentofylline, over 48 weeks. The propentofylline-treated patients showed an improvement in GBS total score which was not significant. There were significant improvements in CGI item II, GDS, SKT and MMSE [&lt;ulink linkID="295098" linkType="reference"&gt;295098&lt;/ulink&gt;]. A meta-analysis has been performed on a combination of the above data and a single-center and a 6-month trial (involving a total of 1273 patients, of whom 625 were on propentofylline). Propentofylline was well tolerated and had beneficial effects in both AD and vascular dementia patients, with significant changes shown in cognitive tests and all global assessments [&lt;ulink linkID="295098" linkType="reference"&gt;295098&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In September 1999, results presented at the 4th International Aging and Dementia Symposium indicated the long-term efficacy of the drug in AD. In a randomized, double-blind, placebo-controlled trial propentofylline was shown to have a significant cognitive effect after 36 weeks, while improvement in the CIBIC+ scale became statistically significant after 24 weeks. The cognitive improvement was maintained for 12 weeks following withdrawal and no relapse to the cognitive baseline was observed. Propentofylline was well tolerated over the 72 weeks of the study. In addition, propentofylline has been shown to inhibit adenosine reuptake and phosphodiesterases, promotes astrocyte differentiation and NGF expression, reduces microglial hyperactivation and has no cholinergic effects [&lt;ulink linkID="342384" linkType="reference"&gt;342384&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A study has evaluated the long-term effects of propentofylline in vascular dementia. Segment I of the study was a 24-week traditional parallel group design followed by a 24-week combined randomized delayed onset/withdrawal of treatment design. A total of 218 propentofylline and 226 placebo patients were enrolled in segment I. In segment II, 93 of the patients who had received placebo in segment I received active treatment and 97 remained on placebo. Also, 83 of patients that received propentofylline during segment I continued to do so, and 82 received placebo. Results were presented at the 6th International Conference on Alzheimer's disease and Related Disorders [&lt;ulink linkID="293662" linkType="reference"&gt;293662&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;One AD study took place in about 30 US centers and involved 450 patients aged 41 and older (with probable AD). A vascular dementia trial enrolled about 225 patients at 28 sites. Both were randomized, double-blind and placebo-controlled, evaluating therapy with oral propentofylline tid. Treatment lasted 1 year in the AD study and 6 months in the vascular dementia study [&lt;ulink linkID="197538" linkType="reference"&gt;197538&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By May 2009, ESAI had shown that the drug could activate stem cells in the hippocampus and coax them through neurogenesis [&lt;ulink linkID="1013956" linkType="Reference"&gt;1013956&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Propentofylline readily passes the blood-brain barrier, and reduces intraneuronal calcium accumulation, reactive astrocytosis, ischemia-induced loss of M1 acetylcholine receptors in the hippocampus and improves ischemia-induced learning deficits. It also antagonizes the action of activated microglial cells including the production of free radicals and beta-amyloid, and stimulates the formation and release of nerve growth factor [&lt;ulink linkID="179878" linkType="reference"&gt;179878&lt;/ulink&gt;]. Studies on rat spinal cord cultured neurons have shown that propentofylline may be useful for the treatment of neurodegenerative diseases related to NO production, by virtue of its ability to raise cAMP levels [&lt;ulink linkID="293777" linkType="reference"&gt;293777&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Despite the discontinuation of this drug for AD, Aventis has published a patent, WO-00007541, claiming the use of propentofylline in erectile dysfunction.&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="25218">Aventis Pharma AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="62">Cerebral infarction</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-05-27T00:00:00.000Z</StatusDate><Source id="288072" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25218">Aventis Pharma AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="540">Arteriosclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-05-27T00:00:00.000Z</StatusDate><Source id="288072" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25218">Aventis Pharma AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-03-06T00:00:00.000Z</StatusDate><Source id="358253" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25218">Aventis Pharma AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-03-06T00:00:00.000Z</StatusDate><Source id="358253" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1047743">Endogenous Stem Cells Activators Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-06-22T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="16807">Hoechst AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="62">Cerebral infarction</Indication><Source id="167545" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16807">Hoechst AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="540">Arteriosclerosis</Indication><Source id="167545" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1047743">Endogenous Stem Cells Activators Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-05-29T00:00:00.000Z</StatusDate><Source id="1013956" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16807">Hoechst AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-12-01T00:00:00.000Z</StatusDate><Source id="197538" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25218">Aventis Pharma AG</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-07-01T00:00:00.000Z</StatusDate><Source id="333420" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25218">Aventis Pharma AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-08-03T00:00:00.000Z</StatusDate><Source id="334895" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25218">Aventis Pharma AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1996-10-11T00:00:00.000Z</StatusDate><Source id="221118" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01518"><Name>PDE</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1047743">Endogenous Stem Cells Activators Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCCn1cnc2c1c(=O)n(c(=O)n2C)CCCCC(=O)C</Smiles></StructureSmiles><Deals><Deal id="126981" title="Endogenous Stem Cells Activators to develop Hoechst's propentofylline"></Deal></Deals><PatentFamilies><PatentFamily id="1138361" number="US-04289776" title="Xanthine Derivatives"></PatentFamily><PatentFamily id="1237309" number="WO-02076460" title="Use of propentofylline to control intraocular pressure"></PatentFamily><PatentFamily id="12523" number="ES-08605809" title="Un Procedimiento De Preparacion De La 1-(5-Oxohexil)-3-Metil-7-Propilxantina"></PatentFamily><PatentFamily id="1315541" number="WO-00071128" title="Compositions and method for decreasing neuropathic pain"></PatentFamily><PatentFamily id="1610979" number="EP-00867192" title="Combinatory compositions for the treatment of dementia containing at least a compound having acetylcholinesterase-inhibitory or muscarinic activity and a compound that enhances the endogenous extracellular adenosine levels"></PatentFamily><PatentFamily id="164406" number="EP-00514789" title="Use of 1-(5-oxohexyl)-3-methyl-7-n-propyl-xanthine in vascular surgery."></PatentFamily><PatentFamily id="1806301" number="EP-01270573" title="Xanthine and phenazone acesulfam-H complexes with improved taste, process for their preparation and their use"></PatentFamily><PatentFamily id="2096410" number="WO-00007541" title="Use Of Xanthine Derivatives For Treating Erectile Disorder"></PatentFamily><PatentFamily id="2727020" number="US-20140121166" title="Compositions and methods for the treatment of juvenile neuronal ceroid lipofuscinosis and related disorders"></PatentFamily><PatentFamily id="328521" number="US-07763626" title="Compositions and method for enhancing the therapeutic activity of opiods in treatment of pain"></PatentFamily><PatentFamily id="3408494" number="WO-2016164719" title="Methods used to treat cancer"></PatentFamily><PatentFamily id="4429785" number="WO-2019055597" title="Methods and compositions for the treatment of tsc"></PatentFamily><PatentFamily id="573541" number="WO-00121178" title="Method of treating cognitive dysfunction syndrome in dogs and chewable tablet for dogs."></PatentFamily><PatentFamily id="615864" number="WO-09207585" title="The use of antibodies to tnf or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor."></PatentFamily><PatentFamily id="654846" number="WO-2007137214" title="Methods for preventing or treating acute and chronic pain"></PatentFamily><PatentFamily id="826741" number="ES-08604961" title="Procedimiento De Obtencion De La 3,7-Dihidro-3-Metil-1-(5-  Oxohexil)-7-Propil-1h-Purina-2,6-Diona"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>8</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Translational Genomics Research Institute" id="1013832"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Solace Pharmaceuticals" id="1034697"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Early Signal Foundation" id="1154951"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="National Tuberous Sclerosis Association Inc" id="1182776"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Akzo Nobel NV" id="13802"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alcon Inc" id="18478"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="UCB SA" id="20452"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dartmouth College" id="20565"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Nebraska" id="20637"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mayo Clinic Foundation" id="21111"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Covex SA" id="24696"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Celanese AG" id="26088"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>